$QPRC
QUEST PATENT RESEARCH CORP Stock $qprc

$qprc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039835 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue		$202.5K	$122.0K
YoY Change		65.98%
Cost Of Revenue	$0.00
YoY Change
Gross Profit	-$97.50K	$14.53K	$11.90K
YoY Change	-587.25%	22.13%
Gross Profit Margin		7.17%	9.75%
Selling, General & Admin	$649.9K	$777.9K	$547.7K
YoY Change	20.91%	42.04%	-75.43%
% of Gross Profit		5354.56%	4604.04%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$229.9K	$158.9K	$308.2K
YoY Change	11.95%	-48.46%	-36.82%
% of Gross Profit		1093.62%	2591.26%
Operating Expenses	$649.9K	$777.9K	$547.6K
YoY Change	20.91%	42.04%	-75.43%
Operating Profit	-$747.4K	-$763.3K	-$535.8K
YoY Change	44.42%	42.48%
Interest Expense	-$422.2K	-$146.0K	$386.0K
YoY Change	-241.9%	-137.83%	-1427.37%
% of Operating Profit
Other Income/Expense, Net	-$422.2K	-$146.0K	$0.00
YoY Change	-241.89%		-100.0%
Pretax Income	-$1.170M	-$909.4K	-$149.8K
YoY Change	431.8%	507.21%	-97.1%
Income Tax		$30.00K	$12.88K
% Of Pretax Income
Net Earnings	-$1.170M	-$939.4K	-$162.6K
YoY Change	431.8%	477.57%	-96.85%
Net Earnings / Revenue		-463.88%	-133.31%
Basic Earnings Per Share	-$0.22	-$0.17	-$0.03
Diluted Earnings Per Share	-$0.22	-$0.17	-$304.90
COMMON SHARES
Basic Shares Outstanding	5.332M shares	5.332M shares	5.332M shares
Diluted Shares Outstanding	5.332M shares	5.332M shares	5.332M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$128.5K	$126.9K	$254.7K
YoY Change	-43.68%	-50.17%	12.18%
Cash & Equivalents	$128.5K	$126.9K	$254.7K
Short-Term Investments
Other Short-Term Assets	$33.36K	$17.92K	$26.69K
YoY Change	12.89%	-32.86%	998.35%
Inventory
Prepaid Expenses	$33.36K
Receivables			$15.41K
Other Receivables			$0.00
Total Short-Term Assets	$161.9K	$144.8K	$296.8K
YoY Change	-37.19%	-51.2%	-66.39%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$4.042M	$4.272M
YoY Change	272.26%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.042M	$4.272M	$1.291M
YoY Change	272.26%	230.86%	-37.41%
TOTAL ASSETS
Total Short-Term Assets	$161.9K	$144.8K	$296.8K
Total Long-Term Assets	$4.042M	$4.272M	$1.291M
Total Assets	$4.204M	$4.417M	$1.588M
YoY Change	212.91%	178.15%	-46.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$206.4K	$171.4K	$147.4K
YoY Change	60.68%	16.27%	-94.1%
Accrued Expenses	$1.254M	$1.040M	$577.6K
YoY Change	85.94%	80.04%	100.16%
Deferred Revenue
YoY Change
Short-Term Debt	$10.03M	$9.535M	$4.601M
YoY Change	30.66%	107.26%	73.81%
Long-Term Debt Due	$2.797M	$2.797M	$2.806M
YoY Change	-0.22%	-0.33%	0.03%
Total Short-Term Liabilities	$14.64M	$13.70M	$9.296M
YoY Change	58.35%	47.34%	-18.76%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K	$149.2K
YoY Change	1.08%	0.54%	-3.72%
Other Long-Term Liabilities	$53.67K	$53.67K	$190.0K
YoY Change	-71.75%	-71.75%	-72.15%
Total Long-Term Liabilities	$203.7K	$203.7K	$339.2K
YoY Change	-39.81%	-39.95%	-59.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.64M	$13.70M	$9.296M
Total Long-Term Liabilities	$203.7K	$203.7K	$339.2K
Total Liabilities	$14.85M	$13.90M	$9.636M
YoY Change	54.89%	44.27%	-21.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.30M	-$27.13M
YoY Change	9.61%
Common Stock	$160.00	$160.00
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$10.64M	-$9.484M	-$8.048M
YoY Change
Total Liabilities & Shareholders Equity	$4.204M	$4.417M	$1.588M
YoY Change	212.91%	178.15%	-46.1%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.170M	-$939.4K	-$162.6K
YoY Change	431.8%	477.57%	-96.85%
Depreciation, Depletion And Amortization	$229.9K	$158.9K	$308.2K
YoY Change	11.95%	-48.46%	-36.82%
Cash From Operating Activities	-$490.2K	-$607.8K	-$210.2K
YoY Change	66.94%	189.21%	-31.29%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$3.300M	-$1.060M
YoY Change		-411.32%	202.86%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$3.300M	-$1.060M
YoY Change		211.32%	202.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	491.7K	$3.944M	1.260M
YoY Change	84.11%	213.03%	98.41%
NET CHANGE
Cash From Operating Activities	-490.2K	-$607.8K	-210.2K
Cash From Investing Activities	0.000	-$3.300M	-1.060M
Cash From Financing Activities	491.7K	$3.944M	1.260M
Net Change In Cash	1.600K	$36.31K	-10.17K
YoY Change	-106.04%	-456.98%	-51.22%
FREE CASH FLOW
Cash From Operating Activities	-$490.2K	-$607.8K	-$210.2K
Capital Expenditures	$0.00	$3.300M	-$1.060M
Free Cash Flow	-$490.2K	-$3.908M	$849.8K
YoY Change	66.94%	-559.84%	1827.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	33-18099-NY
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2873662
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	411 Theodore Fremd Ave
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 206S
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Rye
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10580-1411
CY2023Q1	dei	City Area Code CityAreaCode	(888)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	743-7577
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5331973	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126906	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90601	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	17919	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5321	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	144825	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	95922	usd
CY2023Q1	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1784718	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1625846	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4272282	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1131154	usd
CY2023Q1	us-gaap	Assets Assets	4417107	usd
CY2022Q4	us-gaap	Assets Assets	1227076	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	171374	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	148533	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	138000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	138000	usd
CY2023Q1	qprc	Funding Liability FundingLiability	9397344	usd
CY2022Q4	qprc	Funding Liability FundingLiability	5453204	usd
CY2023Q1	qprc	Loan Payable Related Party LoanPayableRelatedParty	2796500	usd
CY2022Q4	qprc	Loan Payable Related Party LoanPayableRelatedParty	2796500	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	153994	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	145428	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1039849	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	904573	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13697061	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9586238	usd
CY2023Q1	qprc	Loans Payable Sba LoansPayableSba	150000	usd
CY2022Q4	qprc	Loans Payable Sba LoansPayableSba	150000	usd
CY2023Q1	qprc	Purchase Price Of Patents PurchasePriceOfPatents	53665	usd
CY2022Q4	qprc	Purchase Price Of Patents PurchasePriceOfPatents	53665	usd
CY2023Q1	us-gaap	Liabilities Liabilities	13900726	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9789903	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00003
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00003
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5331973	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5331973	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5331973	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5331973	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	160	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	160	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17644852	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17626279	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27128859	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26189494	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-9483847	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8563055	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	228	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	228	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9483619	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8562827	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4417107	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1227076	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	202500	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	122000	usd
CY2023Q1	qprc	Litigation And Licensing Expenses LitigationAndLicensingExpenses	187973	usd
CY2022Q1	qprc	Litigation And Licensing Expenses LitigationAndLicensingExpenses	110105	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	14527	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	11895	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	777857	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	547647	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	777857	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	547647	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-763330	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-535752	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8566	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-471607	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-137469	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-85611	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-146035	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	385996	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-909365	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-149756	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12884	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-939365	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-162640	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5331973	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5331973	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7926723	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	42079	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-162640	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8047284	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8562827	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18573	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-939365	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9483619	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-939365	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-162640	usd
CY2023Q1	qprc	Change In Fair Market Value Of Warrant Liabilitys ChangeInFairMarketValueOfWarrantLiabilitys	8566	usd
CY2022Q1	qprc	Change In Fair Market Value Of Warrant Liabilitys ChangeInFairMarketValueOfWarrantLiabilitys	-471607	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	18573	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	42079	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	158872	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	308226	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15412	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	135276	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	85611	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	12598	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	14383	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	22841	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	17960	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-607835	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-210166	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3300000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1060000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3300000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1060000	usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	1260000	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4000000	usd
CY2023Q1	qprc	Payments To Acquire Purchase Price Of Patents PaymentsToAcquirePurchasePriceOfPatents	55860	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3944140	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1260000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	36305	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10166	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90601	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	264840	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	126906	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	254674	usd
CY2023Q1	qprc	Interest Added To Principal InterestAddedToPrincipal	1387	usd
CY2022Q1	qprc	Interest Added To Principal InterestAddedToPrincipal	1387	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	30000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	12884	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	2193	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Patent Licensing Fees</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers”. Revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Under Topic 606, revenue is recognized when there is a contract which has commercial substance which is approved by both parties and identifies the rights of the parties and the payment terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the periods presented, revenue contracts executed by the Company primarily provided for the payment of contractually determined, one-time, paid-up license fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company’s operating subsidiaries as part of the settlement of litigation commenced by the Company’s subsidiaries. Intellectual property rights granted included the following, as applicable: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. The intellectual property rights granted were perpetual in nature, extending until the legal expiration date of the related patents. The individual intellectual property rights are not accounted for as separate performance obligations, as (a) the nature of the promise, within the context of the contract, is to transfer combined items to which the promised intellectual property rights are inputs and (b) the Company’s promise to transfer each individual intellectual property right described above to the customer is not separately identifiable from other promises to transfer intellectual property rights in the contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the promised intellectual property rights are not individually distinct, the Company combined each individual IP right in the contract into a bundle of IP rights that is distinct, and accounted for all of the intellectual property rights promised in the contract as a single performance obligation. The intellectual property rights granted were “functional IP rights” that have significant standalone functionality. The Company’s subsequent activities do not substantively change that functionality and do not significantly affect the utility of the IP to which the licensee has rights. The Company’s subsidiaries have no further obligation with respect to the grant of intellectual property rights, including no express or implied obligation to maintain or upgrade the technology, or provide future support or services. The contracts provide for the grant (i.e., transfer of control) of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the contract. Licensees legally obtain control of the intellectual property rights upon execution of the contract. As such, the earnings process is complete and revenue is recognized upon the execution of the contract, when collectability is probable and all other revenue recognition criteria have been met. Revenue contracts generally provide for payment of contractual amounts within 30 to 90 days of execution of the contract. Contractual payments made by licensees are generally non-refundable. The Company does not have any significant payment terms, as payment is received shortly after goods are delivered or services are provided, therefore there is no significant financing component or consideration payable to the customer in these transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
CY2022Q1	us-gaap	Other Income Tax Expense Benefit Continuing Operations OtherIncomeTaxExpenseBenefitContinuingOperations	13000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash in bank deposit accounts, which at times, may exceed federally insured limits. The Company has not experienced any such losses in these accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	qprc	Warrants Granted WarrantsGranted	962463	shares
CY2023Q1	qprc	Purchase Agreement Stock Options PurchaseAgreementStockOptions	500000	shares
CY2023Q1	qprc	Stock Options Granted To Officers And Consultants StockOptionsGrantedToOfficersAndConsultants	600000	usd
CY2023Q1	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	27129000	usd
CY2023Q1	qprc	Negative Working Capital NegativeWorkingCapital	13552000	usd
CY2023Q1	qprc	Due To Other Related Partie Current And Noncurrent DueToOtherRelatedPartieCurrentAndNoncurrent	138000	usd
CY2022Q4	qprc	Due To Other Related Partie Current And Noncurrent DueToOtherRelatedPartieCurrentAndNoncurrent	138000	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
CY2023Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	299000	usd
CY2022	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	296000	usd
CY2023Q1	us-gaap	Obligation With Joint And Several Liability Arrangement Amount Outstanding ObligationWithJointAndSeveralLiabilityArrangementAmountOutstanding	5597344	usd
CY2022Q4	us-gaap	Obligation With Joint And Several Liability Arrangement Amount Outstanding ObligationWithJointAndSeveralLiabilityArrangementAmountOutstanding	5453204	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	806000	usd
CY2023Q1	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	56000	usd
CY2023Q1	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	713000	usd
CY2022Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	600000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	962463	shares
CY2023Q1	us-gaap	Short Term Debt Percentage Bearing Variable Interest Rate ShortTermDebtPercentageBearingVariableInterestRate	0.10	pure
CY2022Q2	qprc	Purchase Agreement PurchaseAgreement	92000	usd
CY2022Q3	qprc	Purchase Price Percentage PurchasePricePercentage	0.50	pure
CY2022Q3	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	350000	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	35000	usd
CY2023Q1	qprc	Funding Liability fundingLiability	14000	usd
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	4000000	usd
CY2023Q1	qprc	Requested And Received RequestedAndReceived	500000	usd
CY2023Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	3300000	usd
CY2023Q1	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	25000000	usd
CY2023Q1	qprc	Proceeds From Finance ProceedsFromFinance	3300000	usd
CY2023Q1	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2796500	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2796500	usd
CY2015Q4	qprc	Purchase Agreement PurchaseAgreement	4672810	usd
CY2023Q1	us-gaap	Notes Issued1 NotesIssued1	250000	usd
CY2023Q1	qprc	Loss On Debt Conversion LossOnDebtConversion	305556	usd
CY2023Q1	qprc	Asset Acquired Description AssetAcquiredDescription	Pursuant to the MPA-NA, until the TMPO has been paid in full, Intelligent Partners is entitled to receive 10% of the net proceeds realized from new assets acquired by the Company. If, in any calendar quarter, net proceeds realized exceed $1,000,000, Intelligent Partners’ entitlement for that quarter only shall increase to 30% on the portion of net proceeds in excess of $1,000,000 but less than $3,000,000. If in the same calendar quarter, net proceeds exceed $3,000,000, Intelligent Partners’ entitlement for that quarter only shall increase to 50% on the portion of net proceeds in excess of $3,000,000.
CY2023Q1	qprc	Payments For Loan PaymentsForLoan	275000	usd
CY2023Q1	qprc	Obligation Excess ObligationExcess	1000000	usd
CY2020Q2	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2050-05-14
CY2020Q1	qprc	Deducted Loan Amount DeductedLoanAmount	100	usd
CY2020Q1	qprc	Loan Origination Cost loanOriginationCost	1000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Frequency Of Payment And Payment Terms LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms	$53,665
CY2022	us-gaap	Line Of Credit Facility Frequency Of Payment And Payment Terms LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms	$53,665
CY2023Q1	qprc	Acquisition Funding AcquisitionFunding	95000	usd
CY2023Q1	qprc	Funder Received FunderReceived	53665	usd
CY2021Q1	us-gaap	Shares Issued SharesIssued	962463	shares
CY2021Q1	qprc	Warrant Yield Percentage WarrantYieldPercentage	0.10	pure
CY2021Q1	qprc	Aggregate Number Of Outstanding Shares AggregateNumberOfOutstandingShares	0.10	pure
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	154000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	145000	usd
CY2023Q1	qprc	Fair Value Assumption Expected Volatility Rate FairValueAssumptionExpectedVolatilityRate	3.87	pure
CY2022	qprc	Fair Value Assumption Expected Volatility Rate FairValueAssumptionExpectedVolatilityRate	3.74	pure
CY2023Q1	qprc	Fair Value Assumption Exercise Price FairValueAssumptionExercisePrice	0.0054	pure
CY2022	qprc	Fair Value Assumption Exercise Price FairValueAssumptionExercisePrice	0.0054	pure
CY2023Q1	qprc	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.0137	pure
CY2022	qprc	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.0137	pure
CY2023Q1	qprc	Fair Value Assumption Expected Term FairValueAssumptionExpectedTerm	P7Y10M24D
CY2022	qprc	Fair Value Assumption Expected Term FairValueAssumptionExpectedTerm	P8Y1M6D
CY2023Q1	us-gaap	Impaired Intangible Asset Description ImpairedIntangibleAssetDescription	●patents (which were fully amortized at the date of acquisition) acquired in January 2018 pursuant to an agreement with to Intellectual Ventures Assets 62 LLC and Intellectual Ventures Assets 71 LLC “(IV 62/71”), pursuant to which CXT has an obligation to distribute 50% of net revenues to IV 62/71; ●patents (which were fully amortized at the date of acquisition) acquired in January 2018 by Photonic Imaging Solutions Inc. (“PIS”) from Intellectual Ventures Assets 64 LLC (“IV 64”) pursuant to which PIS is to pay IV 64 (a) 70% of the first $1,500,000 of net revenue, (b) 30% of the next $1,500,000 of net revenue and (c) 50% of net revenue in excess of $3,000,000; ●patents (which were fully amortized at the date of acquisition) acquired in May 2020 for a purchase price of $95,000 pursuant to an agreement with Texas Technology Ventures 2, LLP (“TTV”), pursuant to which of the Company retains the first $230,000 of net proceeds, as defined in the agreement, after which the company has an obligation to distribute 50% of net proceeds to TTV. ●patents (which were fully amortized at the date of acquisition) acquired in February 2021 pursuant to an agreement with PKT for a purchase price of $350,000, pursuant to which $350,000 was paid at closing, and upon the realization of gross proceeds, as defined in the agreement, the Company shall make a subsequent or payments in the aggregate amount of $93,900, representing reimbursement to PKT, as the prosecuting attorney, for legal fees associated with prosecution of the portfolio, such reimbursement shall be due and payable to PKT from time to time as gross proceeds are realized, if any, and paid to PKT along with and in proportion to reimbursement to other third parties of costs incurred in realizing gross proceeds. Thereafter, PKT is entitled to a percentage of gross proceeds realized, if any. ●patents (which were fully depreciated at the date of acquisition) acquired in May 2021 for a purchase price of $250,000.
CY2022Q4	qprc	Warrant Liability WarrantLiability	145428	usd
CY2023Q1	qprc	Gain On Subsequent Measurementin Dollars GainOnSubsequentMeasurementinDollars	8566	usd
CY2023Q1	qprc	Warrant Liability WarrantLiability	153994	usd
CY2023Q1	qprc	Patents Patents	6057000	usd
CY2022	qprc	Patents Patents	2757000	usd
CY2023Q1	qprc	Finite Lived Intangible Assets Total FiniteLivedIntangibleAssetsTotal	6057000	usd
CY2022Q4	qprc	Finite Lived Intangible Assets Total FiniteLivedIntangibleAssetsTotal	2757000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1784718	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1625846	usd
CY2023Q1	qprc	Finite Lived Intangible Asset Net FiniteLivedIntangibleAssetNet	4272282	usd
CY2022Q4	qprc	Finite Lived Intangible Asset Net FiniteLivedIntangibleAssetNet	1131154	usd
CY2023Q1	qprc	Weighted Average Amortization Period Years WeightedAverageAmortizationPeriodYears	P6Y1M28D
CY2022	qprc	Weighted Average Amortization Period Years WeightedAverageAmortizationPeriodYears	P2Y5M23D
CY2021Q4	qprc	Purchase Price PurchasePrice	550000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2022Q1	qprc	Purchase Price PurchasePrice	1060000	usd
CY2022Q3	qprc	Purchase Price PurchasePrice	92000	usd
CY2023Q1	qprc	Purchase Price PurchasePrice	3300000	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	159000	usd
CY2022Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	308000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	626610	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	633222	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	537466	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	496942	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	461663	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	1516380	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4272282	usd
CY2023Q1	qprc	Noncontrolling Interest NoncontrollingInterest	228	usd
CY2022	qprc	Noncontrolling Interest NoncontrollingInterest	228	usd
CY2023Q1	qprc	Noncontrolling Interest NoncontrollingInterest	228	usd
CY2022	qprc	Noncontrolling Interest NoncontrollingInterest	228	usd
CY2023Q1	qprc	Cost Of Service CostOfService	62000	usd
CY2022Q1	qprc	Cost Of Service CostOfService	28000	usd
CY2023Q1	qprc	Annual Bonus Compensation Equal Percentage AnnualBonusCompensationEqualPercentage	0.30	pure
CY2023Q1	us-gaap	Income Loss From Subsidiaries Before Tax IncomeLossFromSubsidiariesBeforeTax	500000	usd
CY2023Q4	qprc	Compensation Percentage CompensationPercentage	0.20	pure
CY2023Q1	us-gaap	Deposits Deposits	16500	usd
CY2022Q1	us-gaap	Deposits Deposits	14500	usd
CY2023Q2	qprc	Operating Expense OperatingExpense	500000	usd
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	QUEST PATENT RESEARCH CORP
CY2023Q1	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt		usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022Q1	qprc	Payments To Acquire Purchase Price Of Patents PaymentsToAcquirePurchasePriceOfPatents		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	qprc	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate		pure
CY2022	qprc	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate		pure
CY2023Q1	us-gaap	Asset Retirement Obligation Period Increase Decrease AssetRetirementObligationPeriodIncreaseDecrease		usd
CY2022	us-gaap	Asset Retirement Obligation Period Increase Decrease AssetRetirementObligationPeriodIncreaseDecrease		usd
CY2023Q1	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity		usd
CY2022Q4	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000824416

Files In Submission

Name	View Source	Status
qprc-20230331_pre.xml	Edgar Link	unprocessable
0001213900-23-039835-index-headers.html	Edgar Link	pending
0001213900-23-039835-index.html	Edgar Link	pending
0001213900-23-039835.txt	Edgar Link	pending
0001213900-23-039835-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_questpatent.htm	Edgar Link	pending
f10q0323ex32-1_questpatent.htm	Edgar Link	pending
f10q0323_questpatent.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qprc-20230331.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qprc-20230331_cal.xml	Edgar Link	unprocessable
qprc-20230331_def.xml	Edgar Link	unprocessable
f10q0323_questpatent_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
qprc-20230331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QPRC
QUEST PATENT RESEARCH CORP Stock $qprc

2023 Q2 Form 10-Q Financial Statement

#000121390023039835 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QPRC QUEST PATENT RESEARCH CORP Stock $qprc

2023 Q2 Form 10-Q Financial Statement

#000121390023039835 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QPRC
QUEST PATENT RESEARCH CORP Stock $qprc